Results 101 to 110 of about 2,249,117 (300)

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Is There a Relationship Between Use of Anti-Vascular Endothelial Growth Factor Agents and Atrophic Changes in Age-Related Macular Degeneration Patients?

Türk Oftalmoloji Dergisi, 2018
Choroidal neovascularization due to age-related macular degeneration (AMD) is currently treated successfully with anti-vascular endothelial growth factor (VEGF) intravitreal agents.
Süleyman Kaynak, Mahmut Kaya, Derya Kaya   +2 more
doaj   +1 more source

Pre‐Regenerative Endothelial Cells Empowered by Antler Blood Exosomes Orchestrate Peripheral Nerve Repair

Advanced Science, EarlyView.
The pre‐regenerative vascular niche (PVN) is essential for nerve repair, yet its endothelial blueprint remains unclear. We identified angiogenic ECs (AECs) as the dominant pre‐regenerative subset and found that antler blood–derived exosomes (AB‐EXO) promote repair via IMP3.
Jinsheng Huang, Qiang Chen, Aihua Jin, Xiaoqi Yang, Hui Zhou, Weiquan Gong, Jin Cheng, Jun Dai, Minjin Wang, Meihua Piao, Yuanyi Wang, Nan Zhou   +11 more
wiley   +1 more source

Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application

, 2015
Yan Zhang,1 Qian Han,2 Yusha Ru,1 Qiyu Bo,1 Rui Hua Wei1 1Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Institute, College of Optometry and Ophthalmology, Tianjin Medical University, Tianjin, 2Tangshan Eye Hospital, Tangshan ...
Bo Q, Han Q, Zhang Y, Ru Y, Wei RH
core  

Clinical preferences and trends of anti‐vascular endothelial growth factor treatments for diabetic macular edema in Japan

Journal of Diabetes Investigation, 2019
Aims/Introduction To determine the current clinical preferences of anti‐vascular endothelial growth factor (VEGF) treatment protocols for diabetic macular edema (DME) in Japan. Materials and Methods This was a descriptive cross‐sectional study.
Masahiko Sugimoto, Hideyuki Tsukitome, Fumiki Okamoto, Tetsuro Oshika, Tetsuo Ueda, Masanori Niki, Yoshinori Mitamura, Hiroto Ishikawa, Fumi Gomi, Shigehiko Kitano, Hidetaka Noma, Masahiko Shimura, Shozo Sonoda, Osamu Sawada, Masahito Ohji, Kozo Harimoto, Masaru Takeuchi, Yoshihiro Takamura, Mineo Kondo, Taiji Sakamoto   +19 more
doaj   +1 more source

Anti-VEGF and Beyond [PDF]

Journal of Ophthalmology, 2017
T. Bertelmann, H. Kaymak, F. T. A. Kretz, M. J. Koss   +3 more
openaire   +3 more sources

Co‐Delivery of Sustained Release Chondroitinase ABC‐37 With Human iPSC‐Derived Neural Progenitors Promotes Transplant Survival and Functional Recovery in a Rodent Model of Stroke

Advanced Science, EarlyView.
A regenerative strategy for stroke combines human stem cell–derived neural progenitor cells with sustained release of a matrix‐modifying, thermostable chondroitinase ABC‐37 enzyme. In a rat model of stroke, co‐delivery enhanced transplanted cell survival and neuronal differentiation, degraded inhibitory extracellular matrix components, and improved ...
Nitzan Letko Khait, David Xinzheyang Li, Keyi Guo, Hong Cui, Quinton Sirianni, Dhana Abdo, Cindi M. Morshead, Molly S. Shoichet   +7 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Single‐Cell Transcriptomic Analysis of Tumor Heterogeneity and the Microenvironment in Pseudomyxoma Peritonei

Advanced Science, EarlyView.
This study presents a single‐cell atlas of pseudomyxoma peritonei spanning primary and paired metastatic lesions. Distinct epithelial substates, stromal remodeling, immune exclusion, lipid metabolic reprogramming, and a candidate angiogenic network were identified in metastatic lesions.
Xi Li, Lei Wang, Lei Ai, Zimeng Li, Zhaochangci Chen, Yuchen Luo, Tianran Zhang, Mengjia Liao, Songhao Wang, Jiajia Cui, Ke Liu, Chengxian Guo, Guodong Liu, Jiye Yin, Wei Wu   +14 more
wiley   +1 more source

A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.

PLoS Medicine, 2008
BackgroundVascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy
Kiyoshi Masuda, Shigetada Teshima-Kondo, Mina Mukaijo, Naoko Yamagishi, Yoshiko Nishikawa, Kensei Nishida, Tomoko Kawai, Kazuhito Rokutan   +7 more
doaj   +1 more source